Supported by
Another Reason to Take Your Blood Pressure Drugs: Lower Dementia Risk
Keeping blood pressure in check may lower the risk of Alzheimer’s disease and other forms of dementia.
Controlling blood pressure in middle age may reduce the risk for dementia.
The benefits of reducing blood pressure to lower the risk for cardiovascular disease are well known, but the role of blood pressure control in dementia has been less certain. Now pooled data from six large observational studies suggests that antihypertensive medicines may lower the risk for Alzheimer’s disease and other forms of dementia. The review is in Lancet Neurology.
The studies involved more than 31,000 participants older than 55, with follow-ups ranging from seven to 22 years. In all, there were 1,741 diagnoses of Alzheimer’s disease and 3,728 cases of other dementias.
Among the 15,537 people with high blood pressure, those using antihypertensive medicine had a 12 percent reduced risk for dementia and a 16 percent reduced risk of developing Alzheimer’s disease. The 15,553 people with normal blood pressure had the same risk for dementia as those who controlled their blood pressure with medicine.
The type of medicine used — diuretics, beta-blockers, calcium channel blockers, ACE inhibitors or angiotensin II receptor blockers — made no difference.
“The most important thing is that level of blood pressure matters,” said the senior author, Lenore J. Launer, a senior investigator with the National Institute on Aging. “If you’re hypertensive, taking medicine may help reduce the risk for dementia. And there’s no evidence that any specific medication is better than any other.”
The Fight Against Alzheimer’s Disease
Alzheimer’s is the most common form of dementia, but much remains unknown about this daunting disease.
How is Alzheimer’s diagnosed? What causes Alzheimer’s? We answered to some common questions.
Determining whether someone has Alzheimer’s usually requires an extended diagnostic process. But new criteria could lead to a diagnosis on the basis of a simple blood test.
The F.D.A. has given full approval to the Alzheimer’s drug Leqembi. Here is what to know about it.
Alzheimer’s can make communicating difficult. We asked experts for tips on how to talk to someone with the disease.
Should you undergo genetic testing to assess your risk for Alzheimer’s? Here’s what to know.
Can your diet counteract cognitive decline? This is what the science says.
Advertisement